Michelle Rosenzwajg | Mcu-Ph
Pierre et Marie Curie University and Medical School

Michelle Rosenzwajg is at the head of the immunomonitoring team of the Clinical Investigation Center in Biotherapy. She is involved in translational research towards a better understanding of immunopathologies and the development from bench to bedside of immunotherapies in the field of cancer and autoimmune diseases. During the last decade, the team has pioneered the clinical use of low-dose IL-2 as a safe Treg inducer in autoimmune diseases Through an expertise in flow cytometry and cellular immunology, she developed methods for deep immunophenotyping to characterized the immune responses in patients included in low-dose IL-2 trials as well as to study the pathophysiology of auto-inflammatory-autoimmune disease continuum which represents a large part of the potential indications of IL2.